Stifel Nicolaus restated their hold rating on shares of Tilray (NASDAQ:TLRY) in a research note issued to investors on Wednesday morning, The Fly reports.
Other equities research analysts have also issued research reports about the stock. Northland Securities restated a hold rating on shares of Tilray in a report on Wednesday. Compass Point lowered their target price on shares of Tilray from $41.00 to $38.00 and set a sell rating for the company in a report on Monday, June 17th. Zacks Investment Research upgraded shares of Tilray from a hold rating to a buy rating and set a $48.00 target price for the company in a report on Tuesday. Oppenheimer initiated coverage on shares of Tilray in a report on Tuesday, June 4th. They issued a market perform rating for the company. Finally, Alliance Global Partners initiated coverage on shares of Tilray in a report on Monday, May 13th. They issued a neutral rating and a $50.00 target price for the company. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company. Tilray has an average rating of Hold and a consensus price target of $67.24.
Tilray stock opened at $31.31 on Wednesday. The firm has a 50-day moving average price of $43.53 and a 200-day moving average price of $54.88. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.06 and a current ratio of 2.04. Tilray has a 12-month low of $28.88 and a 12-month high of $300.00.
Tilray (NASDAQ:TLRY) last released its earnings results on Tuesday, August 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.09). The firm had revenue of $45.90 million during the quarter, compared to the consensus estimate of $40.25 million. Tilray had a negative return on equity of 37.64% and a negative net margin of 121.73%. Tilray’s revenue was up 373.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) EPS. As a group, analysts predict that Tilray will post -0.98 earnings per share for the current fiscal year.
In related news, Director Christine St.Clare sold 4,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $50.01, for a total value of $200,040.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 3.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Lee Financial Co purchased a new position in Tilray in the 1st quarter worth about $25,000. Quantamental Technologies LLC purchased a new position in Tilray in the 1st quarter worth about $26,000. PNC Financial Services Group Inc. increased its stake in Tilray by 105.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 463 shares of the company’s stock worth $30,000 after buying an additional 238 shares during the period. Point72 Asset Management L.P. purchased a new position in Tilray in the 2nd quarter worth about $46,000. Finally, Certified Advisory Corp increased its stake in Tilray by 152.1% in the 2nd quarter. Certified Advisory Corp now owns 1,041 shares of the company’s stock worth $48,000 after buying an additional 628 shares during the period. 2.28% of the stock is currently owned by institutional investors.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
See Also: What is Green Investing?
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.